April 8 Quick Takes: Amphista’s series A; Invitae, Fudan-Zhangjiang and MedGenome

Scottish protein degradation company raises series A

Amphista Therapeutics Ltd. raised $7.5 million in a series A round led by Advent Life Sciences. Seed round funders the Scottish Investment Bank and the European Investment Fund joined the round, along with new investor BioMotiv. The Glasgow-based company, which spun out of Professor Alessio Ciulli’s labs at the University of Dundee, is developing small molecules that cause targeted protein degradation for cancer...